The statin wars: why AstraZeneca must retreat
If you would like a small peek into the complex and powerful realm of pharmaceutical manufacturing and marketing, this editorial should give you a taste. We begin to see how data is manipulated around not for the patient’s benefit, but rather for the bottom line of the shareholders.
The Journal : Back Issues.
